全文获取类型
收费全文 | 7651篇 |
免费 | 448篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 134篇 |
儿科学 | 256篇 |
妇产科学 | 139篇 |
基础医学 | 992篇 |
口腔科学 | 186篇 |
临床医学 | 595篇 |
内科学 | 2003篇 |
皮肤病学 | 84篇 |
神经病学 | 905篇 |
特种医学 | 343篇 |
外科学 | 1029篇 |
综合类 | 30篇 |
一般理论 | 8篇 |
预防医学 | 442篇 |
眼科学 | 149篇 |
药学 | 403篇 |
中国医学 | 14篇 |
肿瘤学 | 427篇 |
出版年
2024年 | 6篇 |
2023年 | 63篇 |
2022年 | 207篇 |
2021年 | 365篇 |
2020年 | 215篇 |
2019年 | 285篇 |
2018年 | 338篇 |
2017年 | 231篇 |
2016年 | 229篇 |
2015年 | 283篇 |
2014年 | 355篇 |
2013年 | 415篇 |
2012年 | 643篇 |
2011年 | 650篇 |
2010年 | 345篇 |
2009年 | 287篇 |
2008年 | 519篇 |
2007年 | 446篇 |
2006年 | 381篇 |
2005年 | 434篇 |
2004年 | 371篇 |
2003年 | 285篇 |
2002年 | 253篇 |
2001年 | 70篇 |
2000年 | 65篇 |
1999年 | 54篇 |
1998年 | 44篇 |
1997年 | 45篇 |
1996年 | 30篇 |
1995年 | 25篇 |
1994年 | 22篇 |
1993年 | 16篇 |
1992年 | 18篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 10篇 |
1985年 | 12篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1977年 | 3篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1969年 | 2篇 |
1968年 | 3篇 |
排序方式: 共有8139条查询结果,搜索用时 31 毫秒
71.
de Diego Rodríguez E del Valle Schaan JI Gutiérrez Baños JL Martín García B Hernández Rodríguez R Portillo Martín JA Correas Gómez MA Roca Edreira A Villanueva Peña A Rado Velázquez MA Hernández Rodríguez A 《Actas urologicas espa?olas》2000,24(10):836-839
Prostatic carcinoma may be diagnosed by the clinic manifestations or by the symptoms for locoregional disemination and distance metastasis. The lymphatic system is the first metastatic station, which is affected in a high percentage of cases. Event it may simulate lymphoproliferatives process and it si uncommon the lymphatic macroaffectation at first. In theses cases, the histologic and immunohistochemical study by the determination of prostatic specific antigen in lymph nodes can provice the diagnosis. Treatment of these tumors is palliative with hormonotherapy. Prognosis is bad with a low survival at five years. 相似文献
72.
The potential use of genetic tests in insurance has raised concerns about discrimination and individuals losing access to health care either because of refusals to test for treatable diseases, or because test-positives cannot afford premiums. Governments have so far largely sought to restrict the use of genetic information by insurance companies. To date the number of tests available with significant actuarial value is limited. However, this is likely to change, raising more clearly the question as to whether the social costs of adverse selection outweigh the social costs of individuals not accessing health care for fear of the consequences of test information being used in insurance markets. In this contribution we set out the policy context and model the potential trade-offs between the losses faced by insurers from adverse selection by insurees (which will increase premiums reducing consumer welfare) and the detrimental health effects that may result from persons refusing to undergo tests that could identify treatable health conditions. It argues that the optimal public policy on genetic testing should reflect overall societal benefit, taking account of these trade-offs. Based on our model, the factors that influence the outcome include: the size of and value attached to the health gains from treatment; deterrent effects of a disclosure requirement on testing for health reasons; incidence of the disease; propensity of test-positives to adverse select; policy value adverse selectors buy in a non-disclosure environment; and price elasticity of demand for insurance. Our illustrative model can be used as a benchmark for developing other scenarios or incorporating real data in order to address the impact of different policies on disclosure and requirement to test. 相似文献
73.
Fabio Scopesi Silvana Canini Cesare Arioni Massimo Mazzella Diego Gazzolo Pasquale B Lantieri Wanda Bonacci Giovanni Serra 《The journal of maternal-fetal & neonatal medicine》2006,19(6):343-346
BACKGROUND: Recently we demonstrated an increased 2,3-diphosphoglycerate (2,3-DPG) erythrocyte concentration in rat pups subjected to nucleotide-enriched artificial feeding. DESIGN: The present study was carried out to test the hypothesis that a possible increase in 2,3-DPG concentration can also be obtained in human neonates who are fed nucleotide-enriched formula. Preterm neonates born or referred to the neonatal intensive care unit of the G. Gaslini Hospital, Genoa University, with a gestational age >30 weeks and <37 weeks were enrolled in our randomized trial. Recruitment took place within 48-72 hours from birth. Only newborns of mothers deciding not to breast-feed were eligible to be randomized for the supplemented group (FN) or non-supplemented group (RF). Breast-fed newborns were considered the control group (C). The study window (for supplementation and blood samples) was restricted to the first two weeks following birth (from the 2nd (t1) to the 16th (t2) day of life). At the end of our study, only 21 neonates were eligible for statistical analysis. RESULTS: The stimulating action of dietary nucleotides on 2,3-DPG concentration failed to be demonstrated; increases in 2,3-DPG concentration that were observed in newborns fed with nucleotide supplemented formula (FN) were comparable to those observed in newborns fed with regular formula (RF) and breast-fed newborns. CONCLUSIONS: The EC recommendation for the amount of nucleotides allowed in formula milk does not seem to be high enough to have positive effects on 2,3-DPG synthesis. Whether this possible 'pharmacological' effect can be achieved by a higher intake of ingested nucleotides and/or a change in the proportions of single nucleotides contained in milk formulas remain interesting end points to be elucidated. 相似文献
74.
75.
Diego Iacono Peter Zandi Myron Gross William R. Markesbery Olga Pletnikova Gay Rudow Juan C. Troncoso 《Oncotarget》2015,6(16):14082-14091
Asymptomatic Alzheimer''s disease (ASYMAD) subjects are individuals characterized by preserved cognition before death despite substantial AD pathology at autopsy. ASYMAD subjects show comparable levels of AD pathology, i.e. β-amyloid neuritic plaques (Aβ-NP) and tau-neurofibrillary tangles (NFT), to those observed in mild cognitive impairment (MCI) and some definite AD cases. Previous clinicopathologic studies on ASYMAD subjects have shown specific phenomena of hypertrophy in the cell bodies, nuclei, and nucleoli of hippocampal pyramidal neurons and other cerebral areas. Since it is well established that the allele APOε4 is a major genetic risk factor for AD, we examined whether specific alleles of APOE could be associated with the different clinical outcomes between ASYMAD and MCI subjects despite equivalent AD pathology. A total of 523 brains from the Nun Study were screened for this investigation. The results showed higher APOε2 frequency (p < 0.001) in ASYMAD (19.2%) vs. MCI (0%) and vs. AD (4.7%). Furthermore, higher education in ASYMAD vs. MCI and AD (p < 0.05) was found. These novel autopsy-verified findings support the hypothesis of the beneficial effect of APOε2 and education, both which seem to act as contributing factors in delaying or forestalling the clinical manifestations of AD despite consistent levels of AD pathology. 相似文献
76.
José Luis Izquierdo Diego Morena Yolanda González José Manuel Paredero Bernardino Pérez Desirée Graziani Matilde Gutiérrez José Miguel Rodríguez 《Archivos de bronconeumologia》2021,57(2):94-100
ObjectiveThe aim of this study was to evaluate the quality of diagnosis and treatment of COPD using Big Data methodology on the Savana Manager 2.1 clinical platform.Materials and methodsA total of 59,369 patients with a diagnosis of COPD were included from a population of 1,219,749 adults over 40 years of age.ResultsIn total, 78% were men. Spirometry data were available for only 26,453 (43.5%) subjects. Disease severity was classified in 18,172 patients: 4396 mild, 7100 moderate, and 6676 severe, although only 27%, 34%, and 28%, respectively, presented obstructive spirometry. The clinical management of COPD is mainly the responsibility of the primary care and pulmonology departments, while internal medicine and, to a lesser extent, geriatrics also participate. Drug treatment was based on bronchodilators and inhaled corticosteroids (ICS). A marked decline in the use of long-acting beta-2 agonists (LABA) in monotherapy and a slight reduction in ICS/LABA combinations, associated with a long-acting anticholinergic (LAMA) in 74% of cases, were observed. All-cause in-hospital mortality among the overall population was 5.6% compared to 1% of the general population older than 40 years. In total, 35% were admitted to hospital, with an average stay of 6.6 days and an in-hospital mortality rate in this group of 10.74%.DiscussionThis study identifies the main features of an unselected COPD population and the main errors made in the management of the disease. 相似文献
77.
78.
79.
Alberto E. Tozzi Lucio Armenio Roberto Bernardini Attilio Boner Mauro Calvani Fabio Cardinale Giovanni Cavagni Arianna Dondi Marzia Duse Alessandro Fiocchi Gian L. Marseglia Michele Miraglia del Giudice Antonella Muraro Giovanni B. Pajno Francesco Paravati Diego Peroni Salvatore Tripodi Alberto G. Ugazio Luciana Indinnimeo 《Pediatric allergy and immunology》2011,22(3):267-276